Analysts rate Mind Medicine Inc. (MNMD:NSD) with a Strong Buy rating and a $3.83 target

HC Wainwright raised the MNMD stock price target to $75 and rates it a Buy.

Based on the Mind Medicine Stock Forecast from 3 analysts, the average analyst MNMD stock price target is USD 3.83 over the next 12 months. Mind Medicine Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of MNMD stock forecast is Very Bearish, which is based on 0 positive signals and 4 negative signals. At the last closing, Mind Medicine stock price was USD 6.12Mind Medicine stock price has changed by -0.88% over the past week, +5.33% over the past month and -82.71% over the last year.

 

About Mind Medicine Inc. (MNMD:NSD):

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in New York, New York.

 

Mind Medicine’s Most Recent Analyst Ratings:

Target Raised by HC Wainwright Buy USD 5 » USD 75 2022-09-21
Initiated Oppenheimer Holdings Outperform USD 3.5 2022-08-26
Maintains HC Wainwright Buy USD 10 » USD 5 2022-08-16
Initiated by Cantor Fitzgerald Securities Overweight USD 3 2022-08-10
Target Lowered by Canaccord Capital Buy USD 5 » USD 4.25 2021-08-18
Initiates Coverage On HC Wainwright Buy USD 10 2021-08-05
Initiates Coverage On Maxim Group Buy USD 6 2021-06-28

 

What we like:

There is nothing we particularly like about the fundamentals of MNMD’s stock.

 

What we don’t like:

Poor risk adjusted returns:

Mind Medicine stock is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns, the returns are unpredictable. Proceed with caution.

Below median dividend returns:

The average income yield of MNMD stock over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow:

MNMD stock had negative total cash flow in the most recent four quarters.

Negative free cash flow:

MNMD stock had negative total free cash flow in the most recent four quarters.